<DOC>
	<DOCNO>NCT00404963</DOCNO>
	<brief_summary>This study represent first administration GSK376501 human goal evaluate initial safety tolerability . The way human body process GSK376501 also determine .</brief_summary>
	<brief_title>A Study To Investigate The Safety And Metabolism Of GSK376501 In Overweight Subjects</brief_title>
	<detailed_description>A Single-Blind , Randomized , Placebo Controlled , Ascending Single Repeat Dose Study Once Daily Dosing Evaluate Safety , Tolerability , Pharmacokinetics , Pharmacodynamics GSK376501 Evaluate Food Effects Relative Bioavailability Tablet Formulation Compared Powder Reconstitution Formulation Healthy Overweight Obese Subjects ( DIX109177 )</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<criteria>Inclusion : Healthy Nonsmoking Overweight obese subject BMI 27 35 . Exclusion : Women pregnant , lactating , childbearing potential</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>GSK376501 ,</keyword>
	<keyword>First Time Human ,</keyword>
	<keyword>Single Dose ,</keyword>
	<keyword>Dose Escalation ,</keyword>
	<keyword>Healthy Overweight/Obese Volunteer</keyword>
</DOC>